Skip to main content
SpringerLink
Log in

Prevention of Type 2 Diabetes

  • Living reference work entry
  • First Online:
Book cover Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment

Part of the book series: Endocrinology ((ENDOCR))

Abstract

Randomized clinical trials in prevention of type 2 diabetes mellitus (T2DM) began as early as the 1960s. This chapter reviews randomized clinical trials in prevention of T2DM since that time. While not comprehensive, this review includes clinical trials with historical interest and a large impact on research in diabetes prevention. I also discuss treatment effects on long-term outcomes beyond diabetes itself. This chapter does not cover nonrandomized prevention activities, bariatric surgery, or randomized clinical trials that aim to prevent or delay type 1 diabetes. This chapter is based, on part, on previous commentaries and reviews I have co-authored with others (Knowler et al. 1995; Crandall et al. 2008; Knowler et al. in press) that include more details on some of the randomized clinical trials described in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Ackermann RT, Holmes AM, Saha C. Designing a natural experiment to evaluate a national health care – community partnership to prevent type 2 diabetes. Prev Chronic Dis. 2013;10:120149.

    Article  Google Scholar 

  • Ackermann RT, Duru OK, Albu JB, Schmittdiel JA, Soumerai WB, Wharam JF, Ali MK, Mangione CM, Gregg ES, NEXT-D Study Group. Evaluating diabetes health policies using natural experiments: the natural experiments for translation in diabetes study. Am J Prev Med. 2015;48:747–54.

    Article  PubMed  PubMed Central  Google Scholar 

  • American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010;33(Suppl 1):S62–9.

    Article  PubMed Central  Google Scholar 

  • Batis C, Rivera JA, Popkin BM, Taillie LS. First-year evaluation of Mexico’s tax on nonessential energy-dense foods: an observational study. PLoS Med. 2016;5:e1002057.

    Article  Google Scholar 

  • Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–280.

    Article  CAS  PubMed  Google Scholar 

  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.

    Article  CAS  PubMed  Google Scholar 

  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA. 2003;290:486–94.

    Article  CAS  PubMed  Google Scholar 

  • Crandall JP, Knowler WC, Kahn SE, Marrero D, Florez JC, Bray GA, Haffner SM, Hoskin M, Nathan DM, for the Diabetes Prevention Program Research Group. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab. 2008;4:382–93.

    Article  PubMed  PubMed Central  Google Scholar 

  • DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Ratner RE, Williams K, Stentz FB, Musi N, Reaven PD. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.

    Article  CAS  PubMed  Google Scholar 

  • Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.

    Article  PubMed Central  Google Scholar 

  • Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes. 2005a;54:1150–6.

    Article  Google Scholar 

  • Diabetes Prevention Program Research Group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes. 2005b;54:2404–14.

    Article  Google Scholar 

  • Diabetes Prevention Program Research Group. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29:2102–7.

    Article  Google Scholar 

  • Diabetes Prevention Program Research Group. Factors associated with diabetes onset during metformin versus placebo therapy in the Diabetes Prevention Program. Diabetes. 2007;56:1153–9.

    Article  Google Scholar 

  • Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes mellitus: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab. 2008;93:4772–9.

    Google Scholar 

  • Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009;374:1677–86.

    Article  PubMed Central  Google Scholar 

  • Diabetes Prevention Program Research Group. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention. Diabetes Care. 2012;35:723–30.

    Article  Google Scholar 

  • Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015a;3:866–75.

    Article  PubMed Central  Google Scholar 

  • Diabetes Prevention Program Research Group. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program Outcomes Study 10-year follow up. J Clin Endocrinol Metab. 2015b;100:1646–53.

    Article  Google Scholar 

  • Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the Diabetes Prevention Program: a randomized controlled trial. Diabetes Care. 2015c;38:51–8.

    Article  Google Scholar 

  • DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holmann RR. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006a;355:1551–62.

    Article  Google Scholar 

  • DREAM Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006b;368:1096–105.

    Article  Google Scholar 

  • Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, for the Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355:241–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.

    Article  CAS  PubMed  Google Scholar 

  • Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, Li H, Li H, Jiang Y, Shuai Y, Zhang B, Zhang J, Gerzoff RB, Roglic G, Hu Y, Li G, Bennett PH. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54:300–7.

    Article  CAS  PubMed  Google Scholar 

  • Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke. 2004;35:1073–8.

    Article  CAS  PubMed  Google Scholar 

  • Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöström L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med. 2000;160:1321–6.

    Article  CAS  PubMed  Google Scholar 

  • Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, the DIAGRAM Consortium, Meigs JB, Altshuler D, Knowler WC, Florez JC, for the Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes. 2011;60:1340–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hivert M-F, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC, for the Diabetes Prevention Program Research Group. Lifestyle and metformin ameliorate insulin sensitivity independently of the genetic burden of established insulin resistance variants in Diabetes Prevention Program participants. Diabetes. 2016;65:520–6.

    Article  CAS  PubMed  Google Scholar 

  • International Expert Committee. International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34.

    Article  Google Scholar 

  • Jablonski KA, McAteer JB, deBakker PIW, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D, Florez JC, for the Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle interventions in the Diabetes Prevention Program. Diabetes. 2010;59:2672–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jarrett RJ, Keen H, Fuller JH, McCartney M. Worsening to diabetes in men with impaired glucose tolerance (“borderline diabetes”). Diabetologia. 1979;16:25–30.

    Article  CAS  PubMed  Google Scholar 

  • Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K. Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet. 2009;373:1607–14.

    Article  CAS  PubMed  Google Scholar 

  • Keen H, Jarrett RJ, Fuller JH. Toldbutamide and arterial disease in borderline diabetics. In: Malaisse WJ, Pirart J, Vallance-Owen J, editors. Proceedings of the eighth congress of the international diabetes federation. Amsterdam: Excerpta Medica; 1974.

    Google Scholar 

  • Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia. 1982;22:73–8.

    Article  CAS  PubMed  Google Scholar 

  • Knowler WC. Prevention of type 2 diabetes: how and in whom? Arch Intern Med. 2011;171:1361–2.

    Article  PubMed  Google Scholar 

  • Knowler WC, Ackermann RT. Preventing diabetes in American Indian communities. Diabetes Care. 2013;36:1820–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Knowler WC, Narayan KM, Hanson RL, Nelson RG, Bennett PH, Tuomilehto J, Scherstén B, Pettitt DJ. Preventing non-insulin-dependent diabetes. Diabetes. 1995;44:483–8.

    Article  CAS  PubMed  Google Scholar 

  • Knowler WC, Sartor G, Melander A, Scherstén B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia. 1997;40:680–6.

    Article  CAS  PubMed  Google Scholar 

  • Knowler WC, Crandall JP, Chiasson J-L, Nathan DM. Prevention of type 2 diabetes. Chapter 38 in Diabetes in America. In: Cowie CC et al (ed). 3rd ed. Bethesda, MD, National Institute of Health, NIH Pub No. 17–1468. (in press).

    Google Scholar 

  • Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152–62.

    Article  PubMed  Google Scholar 

  • Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, Ortiz RV, Wilding JP, Skjøth TV, Manning LS, Pi-Sunyer X, SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399–409.

    Article  PubMed  Google Scholar 

  • Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2:474–280.

    Article  PubMed  Google Scholar 

  • Lindström J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, Keinänen-Kiukaanniemi S, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013;56:284–93.

    Article  PubMed  Google Scholar 

  • Mason CC, Hanson RL, Knowler WC. Progression to type 2 diabetes characterized by moderate then rapid glucose increases. Diabetes. 2007;56:2054–61.

    Article  CAS  PubMed  Google Scholar 

  • McCance DR, Hanson RL, Charles MA, Jacobsson LTH, Pettitt DJ, Bennett PH, Knowler WC. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. Br Med J. 1994;308:1323–8.

    Article  CAS  Google Scholar 

  • Navigator Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010a;362:1463–76.

    Article  Google Scholar 

  • Navigator Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010b;362:1477–90.

    Article  Google Scholar 

  • Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.

    Article  CAS  PubMed  Google Scholar 

  • Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22.

    Article  PubMed  Google Scholar 

  • Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.

    Article  CAS  PubMed  Google Scholar 

  • Saito T, Watanabe M, Nishida J, Izumi T, Omura M, Takagi T, Fukunaga R, Bandai Y, Tajima N, Nakamura Y, Ito M, Zensharen Study for Prevention of Lifestyle Diseases Group. Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. Arch Intern Med. 2011;171:1352–60.

    Article  PubMed  Google Scholar 

  • Sartor G, Scherstén B, Carlström S, Melander A, Nordén A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29:41–9.

    Article  CAS  PubMed  Google Scholar 

  • Stevenson M, Thompson J, Hérick de Sá T, Ewing R, Mohan D, McClure R, Roberts I, Tiwari G, Giles-Corti B, Sun X, Wallace M, Woodcock J. Urban design, transport, and health 2: land use, transport, and population health: estimating the health benefits of compact cities. Lancet. 2016;388:2925–35.

    Article  PubMed  PubMed Central  Google Scholar 

  • Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373:2215–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.

    Article  CAS  PubMed  Google Scholar 

  • Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M, Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.

    Article  CAS  PubMed  Google Scholar 

  • Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Valle TT, Eriksson JG, Tuomilehto J, Finnish Diabetes Prevention Study Group. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study–secondary analysis of the randomized trial. PLoS One. 2009;4:e5656.

    Article  PubMed  PubMed Central  Google Scholar 

  • Vijayakumar P, Nelson RG, Hanson RL, Knowler WC, Sinha M. HbA1c and the prediction of type 2 diabetes in children and adults. Diabetes Care. 2017;40:16–21.

    Article  CAS  PubMed  Google Scholar 

  • Wareham NJ, Herman WH. The clinical and public heath challenges of diabetes prevention: a search for sustainable solutions. PLoS Med. 2016;10:e1002097.

    Article  Google Scholar 

  • Warren B, Pankow JS, Matsushita K, Punjabi NM, Daya NR, Grams M, Woodward M, Selvin E. Comparative prognostic performance of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2017;5:34–42.

    Article  PubMed  Google Scholar 

  • White M. Population approaches to prevention of type 2 diabetes. PLoS Med. 2016;13:e1002080.

    Article  PubMed  PubMed Central  Google Scholar 

  • World Health Organization. Diabetes mellitus: report of a WHO study group. WHO Tech Rep Ser. 1985;727:7–113.

    Google Scholar 

  • Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B, HOPE Study Investigators. Ramipril and the development of diabetes. JAMA. 2001;286:1882–5.

    Article  CAS  PubMed  Google Scholar 

  • Zinman B, Harris SB, Neuman J, Gerstein H, Retnakaran RR, Raboud J, Qi Y, Hanley AJG. Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomized controlled study. Lancet. 2010;376:103–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases.

Author information

Authors and Affiliations

  1. Diabetes Epidemiology and Clinical Research Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA

    William C. Knowler

Authors
  1. William C. Knowler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William C. Knowler .

Editor information

Editors and Affiliations

  1. Endocrinology, Diabetes and Metabolism, University of Verona, Verona, Italy

    Enzo Bonora

  2. Diabetes Division, UTHSCSA, San Antonio, Texas, USA

    Ralph DeFronzo

Rights and permissions

Reprints and permissions

Copyright information

© 2018 This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Knowler, W.C. (2018). Prevention of Type 2 Diabetes. In: Bonora, E., DeFronzo, R. (eds) Diabetes. Epidemiology, Genetics, Pathogenesis, Diagnosis, Prevention, and Treatment. Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-319-27317-4_16-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27317-4_16-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27317-4

  • Online ISBN: 978-3-319-27317-4

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation